Protocols
ASTELLAS-2138-CL-0101 Phase I OPEN TO ACCRUAL
A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination with Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with mFOLFIRINOX in Participants with Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
HCRN-GI18-333-SEQUEL Phase II OPEN TO ACCRUAL
Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) with Anti-Angiogenesis and Chemotherapy in Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
HOFFMANN-BO41932-TAPISTRY Phase II OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
IIT-GEORGE-I-PREDICT Phase I/II OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
MAYO-18-1612-BIOREPOSITORY Phase N/A OPEN TO ACCRUAL
Exploration of tumor biology in patients with metastatic esophageal and gastric cancer (biorepository protocol for prospective tissue collection)
MERCK-MK1084-001 Phase I OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Subjects with KRAS G12C Mutant Advanced Solid Tumors
NRG-GY022 Phase I OPEN TO ACCRUAL
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
XILIO-XTX301-01-02-001 Phase I OPEN TO ACCRUAL
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors